Vnitr Lek 2018, 64(2):164-168 | DOI: 10.36290/vnl.2018.024

Novel trends in monitoring and therapy of ANCA associated vasculitides

Radim Bečvář
Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

Vasculitides with positivity of autoantibodies to neutrophil leukocytes cytoplasm (ANCA, AAV) belong to primary vasculitides involving small and less commonly medium size blood vessels. Three different clinical types of AAV can be distinguished: granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis. Since these autoantibodies seem to be weak activity biomarkers of AAV new molecules and factors start to come up, e.g. neutrophil extracellular traps NET, several T-lymphocyte subpopulations and different immunoglobulins classes of ANCA. In modern biological therapy rituximab is widely used, for refractory cases intravenous immunoglobulins and antithymocyte globulin are recommended. The data from clinical trials with alemtuzumab are controversial, but avacopan selective inhibitor of C5a receptor and inhibitor of B-lymphocyte activation factor belimumab are promise for future.

Keywords: biologicals; biomarkers; eosinophilic granulomatosis with polyangiitis; granulomatosis with polyangiitis; microscopic polyangiitis

Received: September 22, 2017; Accepted: November 19, 2017; Published: February 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bečvář R. Novel trends in monitoring and therapy of ANCA associated vasculitides. Vnitr Lek. 2018;64(2):164-168. doi: 10.36290/vnl.2018.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bečvář R, Tesař V, Rychlík I. Vaskulitidy v klinické praxi - diagnostika a terapie. Medprint: Praha 1994: 90-102.
    2. Ansell BM (ed), Bacon PA, Lie JT et al. The vasculitides. Science and practice. Springer 1996, 267-269. ISBN-10: 0412641402. ISBN-13: 978-0412641404.
    3. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116(6): 488-498. Go to original source... Go to PubMed...
    4. Cockwell P, Savage CO. Wegener's granulomatosis. Pathogenesis. In: Hoffman GS, Weyand CM (eds). Inflammatory diseases of blood vessels. Marcel Dekker: New York 2002: 365-380. ISBN 978-0824702694. Go to original source...
    5. Bečvář R. Eozinofilní granulomatóza s polyangiitidou. In: Pavelka K et al (ed) Revmatologie. Maxdorf: Praha 2012: 408-410. ISBN 978-80-7345-295-7.
    6. Specks U. Churg-Strauss syndrome. In: Ball GV, Louis Bridges S Jret al (eds) Vasculitis. 2nd ed. New York: Oxford University Press 2008: 429-438. ISBN 978-0198570196.
    7. Bečvář R. Mikroskopická polyangiitida. In: Pavelka K et al. Revmatologie. 2nd ed. Galén: Praha 2010: 67-68. ISBN 978-80-7262-688-5.
    8. Heeringa P, Jennette JC et al. Microscopic polyangiitis: Pathogenesis. In: Hoffman GS, Weyand CM (eds). Inflammatory diseases of blood vessels. Marcel Dekker: New York 2002: 339-354. ISBN 978-0824702694. Go to original source...
    9. Brogan P, Eleftheriou D. Vasculitis update: pathogenesis and biomarkers. Pediatr Nephrol 2018; 33(2): 187-198. Dostupné z DOI: <http://dx.doi.org/10.1007/s00467-017-3597-4>. Go to original source... Go to PubMed...
    10. Panda R, Krieger T, Hopf L al. Neutrophil extracellular traps contain selected antigens of anti-neutrophil cytoplasmic antibodies. Front Immunol 2017; 8: 439. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2017.00439>. Go to original source... Go to PubMed...
    11. Natorska J, Ząbczyk M, Siudut J et al. Neutrophil extracellular traps formation in patients with eosinophilic granulomatosis with polyangiitis: association with eosinophilic inflammation. Clin Exp Rheumatol 2017; 35(1 Suppl 103): S27-S32.
    12. Zhou XL, Zheng MJ, Shuai ZW et al. The significances of peripheral neutrophils CD(55) and myeloperoxidase expression in patients with myeloperoxidase-specific anti-neutrophil cytoplasmic antibody associated vasculitis. Zhonghua Nei Ke Za Zhi 2017; 56(6): 427-432. Dostupné z DOI: <http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2017.06.008>.
    13. Szczeklik W, Jakieła B, Wawrzycka-Adamczyk K. Skewing toward Treg and Th2 responses is a characteristic feature of sustained remission in ANCA-positive granulomatosis with polyangiitis. Eur J Immunol 2017; 47(4): 724-733. Dostupné z DOI: <http://dx.doi.org/10.1002/eji.201646810>. Go to original source... Go to PubMed...
    14. Clain JM, Hummel AM, Stone JH et al. Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. Clin Exp Immunol 2017; 188(1): 174-181. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12925>. Go to original source... Go to PubMed...
    15. Bečvář R. Moderní terapie ANCA pozitivních vaskulitid. Acta medicinae 2013; 2(5): 76-79.
    16. Faurschou M, Westman K, Rasmussen N et al. [European Vasculitis Study Group]. Brief report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64(10): 3472-3477. Dostupné z DOI: <http://dx.doi.org/10.1002/art.34547>. Go to original source... Go to PubMed...
    17. Hu W, Liu C, Xie H et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008; 23(4): 1307-1312. Dostupné z DOI: <http://dx.doi.org/10.1093/ndt/gfm780>. Go to original source... Go to PubMed...
    18. Pepper RJ, Chanouzas D, Tarzi, R et al. [European Vasculitis Study (EUVAS) investigators] Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013; 8(2): 219-224. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.03680412>. Erratum in Clin J Am Soc Nephrol 2013; 8(4): 701. Caisian A. Go to original source... Go to PubMed...
    19. Smith RM, Jones RB, Jayne DR. Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther 2012; 4(2): 210. Dostupné z DOI: <http://dx.doi.org/10.1186/ar3797>. Go to original source... Go to PubMed...
    20. Stone J, Uhlfelder M, Hellmann D et al. Etanercept with conventional treatment in Wegener's granulomatosis: A six month open-label trial to evaluate safety. Arthritis Rheum 2001; 44(5): 1149-1154. Dostupné z DOI: <http://dx.doi.org/10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F>. Go to original source...
    21. Jones RB, Tervaert JW, Hauser T et al. [European Vasculitis Study Group[. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Eng J Med 2010; 363(3): 211-220. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0909169>. Go to original source... Go to PubMed...
    22. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide forANCA-associated vasculitis. N Eng J Med 2010; 363(3): 221-232. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0909905>. Go to original source... Go to PubMed...
    23. Luqmani R. Maintenance of remission in ANCA-associate vasculitis. Nat Rev Rheumatol 2013; 9(2): 127-132. Dostupné z DOI: <http://dx.doi.org/10.1038/nrrheum.2012.188>. Go to original source... Go to PubMed...
    24. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008; 67(9): 1322-1327. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2007.081661>. Go to original source... Go to PubMed...
    25. Jayne RWD, Bruchfeld AN, Harper L et al. [CLEAR Study Group]. Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28(9): 2756-2767. Dostupné z DOI: <https://doi.org/10.1681/ASN.2016111179>. Go to original source... Go to PubMed...
    26. Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther 2015; 9: 333-347. Dostupné z DOI: <http://dx.doi.org/10.2147/DDDT.S67264>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.